Increasing the efficacy of PD-1 inhibitors in HL using combination strategies

David Bond, MD, The Ohio State University Comprehensive Cancer Center, Columbus, OH, summarizes various combination approaches being explored with PD-1 inhibitors for the treatment of Hodgkin lymphoma (HL), including combinations with LAG-3 inhibitors, chemotherapy, and antibody-drug conjugates (ADCs). This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.